Pharmaceutical companies’ aggressive marketing of expensive (and profitable) medications has likely exacerbated America’s problems with health care.
The tactics some have used in convincing doctors to write more prescriptions are questionable.
It’s a difficult number to quantify, but there’s no doubt that unnecessary prescriptions of expensive medications have cost taxpayers a significant amount through Medicare and Medicaid patient billings.
Most of these issues have fallen into a gray area of the law and medical ethics, and haven’t, frankly, been seen as a pressing enough public policy issue to prompt significant reform.
The case of Heather Alfonso should change that in Connecticut and beyond.
As chronicled in some excellent reporting by the Connecticut Health Investigative Team’s Lisa Chedekel, Alfonso recently showed up as the top Medicare-billable prescriber in Connecticut of Schedule II narcotics. She was also on a list of the top 10 highest prescribers in the country of a drug called Subsys. It’s a pain killer intended for cancer patients that includes the opioid Fentanyl.
Opioid overdoses killed at least 307 people in Connecticut last year, and 257 the year before. Experts have identified a pattern of patients getting hooked on prescription painkillers and then switching to a cheaper substitute — heroin. Sports Illustrated recently wrote about how the problem is spreading even to high school athletes who get prescriptions to deal with sports injuries.
Alfonso, who worked at the Comprehensive Pain and Headache Treatment Center in Derby, pleaded guilty Tuesday to accepting $83,000 in kickbacks from January 2013 to March 2015 in exchange for pushing Subsys. According to Chedekel’s reporting, Alfonso was prescribing it to non-cancer patients who complained of chronic pain, and wrote “about $1.6 million in prescriptions” for it over the course of two years.
Considering the likely profit margins on a drug such as Subsys, that’s a pretty good return on investment for Insys Therapeutics, the Arizona company that makes the drug.
It paid Alfonso for “more than 70 ‘dinner programs,’ at a rate of approximately $1,000 per event.” This is a common thing between drug companies and physicians. They are paid as consultants, speakers at conferences, and so on. Except, according to Chedekel, Alfonso and a drug company rep were often the only people in attendance at these “dinner programs,” and she never really gave any kind of speech or presentation or consultation about the drug.
Alfonso is in trouble for defrauding the taxpayer-funded Medicare and Medicaid programs — pushing prescriptions not because they were the best medical option but because she was getting kickbacks from a drug company.
Connecticut and other communities across the country struggling with opioid abuse should consider far more serious charges against medical professionals who do this and drug companies such as Insys who “influence” them.
It’s not about Medicare fraud or bloated health care costs anymore. It’s greed leading to the death of our friends and neighbors.
Support authentic, locally owned and operated public service journalism!
Matt DeRienzo is a media industry consultant who lives in Litchfield. He is the former editor of Digital First Media’s publications in Connecticut, including the New Haven Register, Register Citizen of Torrington, Middletown Press and Connecticut Magazine.
DISCLAIMER: The views, opinions, positions, or strategies expressed by the author are theirs alone, and do not necessarily reflect the views, opinions, or positions of CTNewsJunkie.com.
More Health Care News & Analysis
Medical Examining Board Fines Doctor $10,000
The state Medical Examining Board on Tuesday fined an Oxford doctor $10,000 for fraudulently using another doctor’s name and Drug Enforcement Agency registration number to prescribe controlled substances to a family member.
Keep reading
Clinical Trials With Immunotherapy Drugs Are Source Of Hope And Challenges In Treating Aggressive Breast Cancer
Joshalyn Mills of Branford and Nancy Witz of Kensington had the best possible results after being treated in clinical trials with immunotherapy drugs for aggressive breast cancer: Their tumors were eliminated. But while there are dramatic successes with immunotherapy drugs, there are also many failures, and researchers are trying to find out why in hopes…
Keep reading
Coalition of Health Insurers Questions Viability of Connecticut Partnership Plan
Members of Connecticut’s Health Care Future, a coalition of health insurers, hospitals, and businesses, are questioning whether Connecticut lawmakers have done enough this year to protect teachers and municipal employees from increases in health insurance premiums. “Despite repeated bailouts from taxpayers, the Connecticut Partnership Plan continues to be a fiscal Titanic that demonstrates why government-controlled health…
Keep reading
AG’s Tackle Mental Health Parity
Attorneys General in Connecticut and Rhode Island threw their support Monday behind a coalition of mental health advocacy groups asking a federal appeals court to revisit a recent ruling giving insurance companies more flexibility to deny mental health claims.
Keep reading
Budget Green Lights Psychedelic Therapies
Buried in the budget Gov. Ned Lamont signed this week is a provision that would create a pilot program to allow Connecticut to be the first-in-the-nation to study the impact of psychedelic drugs like psilocybin and MDMA on patients with depression and PTSD. The budget now creates a pilot program within the Department of Mental…
Keep reading
Officials Highlight Effort To Boost Mental Health Services For Kids
At a Hartford-based community provider Wednesday, Gov. Ned Lamont and a handful of his agency commissioners highlighted the expected impact of more than $100 million in recently passed funding aimed at increasing behavioral health services for Connecticut children. The governor appeared at The Village for Families and Children, a recipient of new state funding included…
Keep reading